Premium
Predicting treatment outcome following 24 weeks peginterferon α‐2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV‐RNA at day 0, day 22, day 29, and week 6
Author(s) -
Lukasiewicz Esther,
Hellstrand Kristoffer,
Westin Johan,
Ferrari Carlo,
Neumann Avidan U.,
Pawlotsky Jeanmichel,
Schalm Solko W.,
Zeuzem Stefan,
Veldt Bart J.,
Hansen Bettina E.,
Verheyhart Elke,
Lagging Martin
Publication year - 2007
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.21505
Subject(s) - ribavirin , medicine , peginterferon alfa 2a , gastroenterology , viremia , viral load , combination therapy , genotype , odds ratio , virology , hepatitis c virus , virus , biology , biochemistry , gene
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom